Scholarlink

Background <p>Patients with inflammatory bowel disease (IBD) face an elevated risk of colorectal cancer (CRC). Statins have demonstrated potential anticancer properties, but evidence in IBD populations remains limited.</p> Objective <p>To evaluate the association between sustained statin use and the risk of CRC in patients with IBD, and to assess dose–response relationships and statin type-specific effects.</p> Design <p>Nationwide, retrospective cohort study using time-dependent Cox proportional hazards models and Fine–Gray competing risk models.</p> Results <p>Among 6,120 propensity score–matched adults with IBD (2,040 statin users and 4,080 non-statin lipid-lowering agent users), statin use was associated with a 65% reduction in CRC risk compared with users of non-statin lipid-lowering agents (adjusted hazard ratio [aHR] 0.35; 95% CI, 0.24–0.52; <i>p</i>&lt;0.0001). A clear dose–response relationship was observed, with the highest quartile of cumulative exposure associated with an aHR of 0.08. Rosuvastatin and simvastatin conferred the strongest protective effects. Statin use also correlated with lower all-cause mortality (aHR 0.42; 95% CI, 0.35–0.51).</p> Conclusion <p>In this nationwide observational cohort, sustained statin use was associated with a significantly lower risk of CRC and mortality. While the observed dose–response and statin-specific patterns suggest a potential chemopreventive signal, these findings are hypothesis-generating. Confirmation in randomized or pragmatic trials is required before these results can translate into clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dose–response effect of statins on colorectal cancer risk in IBD: a nationwide cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月10日

查看全文
  • Yan-Jiun Huang,
  • Han-Hsiang Lee,
  • Wan-Ming Chen,
  • Szu-Ming Peng,
  • Qiu-Yang Zhang,
  • Ben-Chang Shia,
  • Szu-Yuan Wu

摘要

Background

Patients with inflammatory bowel disease (IBD) face an elevated risk of colorectal cancer (CRC). Statins have demonstrated potential anticancer properties, but evidence in IBD populations remains limited.

Objective

To evaluate the association between sustained statin use and the risk of CRC in patients with IBD, and to assess dose–response relationships and statin type-specific effects.

Design

Nationwide, retrospective cohort study using time-dependent Cox proportional hazards models and Fine–Gray competing risk models.

Results

Among 6,120 propensity score–matched adults with IBD (2,040 statin users and 4,080 non-statin lipid-lowering agent users), statin use was associated with a 65% reduction in CRC risk compared with users of non-statin lipid-lowering agents (adjusted hazard ratio [aHR] 0.35; 95% CI, 0.24–0.52; p<0.0001). A clear dose–response relationship was observed, with the highest quartile of cumulative exposure associated with an aHR of 0.08. Rosuvastatin and simvastatin conferred the strongest protective effects. Statin use also correlated with lower all-cause mortality (aHR 0.42; 95% CI, 0.35–0.51).

Conclusion

In this nationwide observational cohort, sustained statin use was associated with a significantly lower risk of CRC and mortality. While the observed dose–response and statin-specific patterns suggest a potential chemopreventive signal, these findings are hypothesis-generating. Confirmation in randomized or pragmatic trials is required before these results can translate into clinical practice.